NCT03803761 2023-09-25
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)